Latent Health is tapping into the $200 billion market for specialty drugs with AI agents that help doctors convince insurers ...

Mass spectrometry is already a powerful tool for determining what kind and how many molecules are present in a given sample. But most instruments still analyze their molecules one or just a few at a ...

Although phosphorylated tau at threonine 231 (pTau 231) is a promising blood-based biomarker for incipient Alzheimer's disease (AD), existing assays such as Simoa® are not sensitive enough to reliably ...